Clinical trial
A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo
NCT05247489 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo
- Lead sponsor
- Incyte Corporation
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 5, 2022
- Completion date
- December 19, 2023
- Enrollment
- 55 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.